/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.
Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.
Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
/Abbvie%20Inc%20HQ%20photo-by%20vzphotos%20via%20iStock.jpg)
Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Gilead Sciences has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.
/AMGEN%20Inc_%20HQ%20sign-%20by%20JHVEPhoto%20via%20iStock.jpg)
Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Abbvie%20Inc%20billboard%20-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.